07 Feb 19

NEWS

Shore Capital acted as Joint Bookrunner on a £100m placing and
c.£7m open offer for Randall & Quilter Investment Holdings Ltd

Randall & Quilter Investment Holdings Ltd. ("R&Q", the "Group" or the "Company") Placing and open offer to raise up to approximately £107 million   Randall & Quilter Investment Holdings Ltd., the global program underwriting management and legacy acquisitions specialist,

06 Feb 19

NEWS

Shore Capital acted as Nomad, Sole Bookrunner raising £10m for SysGroup

    Acquisition of Certus IT Limited (“Certus”), Placing of 26,315,792 new ordinary shares to raise approximately £10.0 million,  new £5.0 million banking facilities, related party transaction and  Notice of General Meeting   SysGroup, the aw

01 Feb 19

NEWS

Howard Shore on Bloomberg Surveillance, 1 February 2019

  Howard Shore discusses his support for the Conservative party and his thoughts on Brexit, including the possibility of a hard Brexit, a hard border for Ireland and the scope for compromise. Howard Shore on Bloomberg Surveillance  

25 Jan 19

NEWS

Shore Capital acted as Lead Manager, successfully raising c.US$23 million for Savannah Petroleum PLC

  Savannah Petroleum PLC ("Savannah" or "the Company")   Savannah Successfully Raises c.US$23 million Savannah Petroleum PLC, the British independent company focused around activities in Niger and Nigeria, is pleased to confirm the successful completion of its proposed placing, as a

16 Jan 19

NEWS

72 Shopping Days to a No Deal Brexit: The Mexican stand-off continues

By: Matthew Elliott, Senior Political Adviser   The British Government’s defeat in the Meaningful Vote by 230 votes (with 202 in favour and 432 against) is the biggest defeat suffered by a Government since records began and is at the very top end of where expectations were set ahead of

04 Jan 19

NEWS

Women Inspired Network Afternoon Tea for AIM Professionals

  Towards the end of 2018, members of the Shore Capital team attended the Women Inspired Network (WIN) Afternoon Tea for AIM professionals, hosted at the London Stock Exchange.    WIN is London Stock Exchange’s global network which was launched in 2015, in order to

02 Jan 19

NEWS

Shore Capital appointed as Joint Broker to Eagle Eye Solutions Group Plc

  Shore Capital is delighted to have been appointed as Joint Broker to Eagle Eye Solutions Group Plc, with a market cap of £26.5m. Eagle Eye is a leading SaaS technology company that allows businesses to create a real-time connection to attract and retain their customers through digital

12 Dec 18

NEWS

WPP restructuring must gain traction before stock valued higher, says Roddy Davidson

Roddy Davidson, media analyst at Shore Capital, discusses the announcement that WPP will cut 3,500 jobs in a $382 million restructuring.   WPP restructuring must gain traction before stock valued higher, analyst says from CNBC.

07 Dec 18

NEWS

Shore Capital acted as Nomad and Joint Bookrunner, raising £19m for Inspired Energy

7 December 2018   Inspired Energy plc ("Inspired", or the "Company") Completion £19.0 million Placing for the Company Posting of Shareholder Circular and Notice of General Meeting   Further to the earlier announcement, Inspired (AIM: INSE), a leading energy procurement consu

06 Dec 18

NEWS

Shore Capital appointed as Nomad and Sole Broker to Titon Holdings Plc

      Shore Capital has been appointed as Nominated Adviser and Sole Broker to Titon Holdings plc with effect from its admission to AIM on 10 December 2018.   About Titon Holdings plc Titon is an international manufacturer and supplier of ventilation systems and window and

30 Nov 18

NEWS

Shore Capital acted as Joint Global Coordinator on the secondary placing of 4 million shares in Global Ports Holding Plc

    GLOBAL PORTS HOLDING PLC ("GPH PLC" or the "Company") Results of secondary placing of ordinary shares in GPH PLC     Further to the announcement released yesterday, GPH PLC has been advised by Global Yatırım Holding A.Ş. ("GIH"), that its wholly-owned subsidiary,

19 Oct 18

NEWS

Life Science Analysis: RNA therapeutics are now a clinical reality

After nearly two decades in development, RNA therapeutics are now a clinical reality.  Shore Capital’s Healthcare Analyst, Tara Raveendran, discusses how the approval of these RNA-based therapeutics marks the start of the next chapter in what has been a rollercoaster ride for this novel

1 2 3